|
- BioNTech
BioNTech guides you through the promising world of immunotherapies Find information on basic research and new developments of new treatment options
- BioNTech Completes Acquisition of Biotheus | BioNTech
Biotheus will operate as a new indirect Chinese subsidiary of BioNTech, adding a local research and development hub and an advanced biologics manufacturing facility to the Company’s network
- BioNTech to wind down cell therapy manufacturing in Maryland
Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U S plant
- BioNTech Clinical Trials | Advancing Health Through Innovation
Discover how BioNTech is pioneering novel medicines for cancer and infectious diseases Learn more about our clinical trials, the importance of participation, and how to get involved in advancing global health
- BioNTech SE to Release Second Quarter 2025 Financial Results . . . - Nasdaq
BioNTech will announce Q2 2025 financial results on August 4, followed by a conference call and webcast Quiver AI Summary BioNTech SE will release its financial results for the second quarter of
- Bristol Myers agrees up to $11. 1 billion deal with BioNTech to shake up . . .
June 2 (Reuters) - Bristol Myers Squibb (BMY N) has agreed to pay up to $11 1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could
- BioNTech SE Company Profile - Overview - GlobalData
BioNTech's product portfolio includes investigational mRNA vaccines, protein-based therapeutics, cell therapies, and small molecules Its first marketed product is Comirnaty The company's products are designed to address the needs of cancer patients and combat infectious diseases
- BioNTech US
BioNTech US is a fully integrated subsidiary with a strong foundation in Europe and a focus on the development of novel neoantigen-targeted T cell therapies, complementing BioNTech’s highly innovative scientific approach and diversified pipeline of transformative cancer medicines
|
|
|